Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...
Why the latest soquelitinib data matters for Corvus Pharmaceuticals (CRVS) Corvus Pharmaceuticals (CRVS) just reported positive cohort 4 Phase 1 data for soquelitinib in moderate to severe atopic ...
4h
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
Early eczema trial success and heavy trading are rapidly reshaping how investors view this drug developer, today, Jan. 20, ...
Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...
Analyzing patient health care notes recorded during millions of medical appointments at GPs and hospitals across England has ...
Corvus Pharma (CRVS) stock surges as the company plans a Phase 2 trial for its lead asset against eczema following ...
Preclinical in vivo efficacy data in atopic dermatitis extend previous PoC in allergic asthmaPositive opinion from the ...
Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...
Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...
A study published in Nutrition Reviews in November 2025 found evidence linking oral probiotics and synbiotics to improvements in atopic dermatitis (AD) symptoms. However, research for other skin ...
Winters are known to worsen symptoms of eczema due to dropping temperatures.It is believed that around 8 million people in ...
Analysis found patients diagnosed with eczema were more likely to also be diagnosed with eye conditions and inflammatory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback